Cord blood CAR cells for hard-to-treat B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1/2 study tests cord blood–derived CAR NK cells that are designed to attack lymphoma cells marked with CD19 and/or CD70. It is for people whose B-cell non-Hodgkin lymphoma has come back or did not respond to prior treatment, including CAR-T when applicable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must agree to join and sign informed consent
- Age 18–75, and you must have certain B-cell lymphomas confirmed by pathology (DLBCL, tFL, PMBCL, MCL, or related transforming types)
- Your cancer must have returned or not responded after specific prior therapies (including timing rules) and you must have at least one measurable tumor spot ≥ 1.5 cm
- You must have proof the lymphoma cells are CD19+ or CD70+ (or both)
- Your body must be healthy enough for treatment: good kidney/liver function, adequate blood counts, heart pumping strength ≥45%, and oxygen level >92% on room air
- You must not have certain infections or major health conditions (like HIV, hepatitis B/C, active serious infection, significant heart failure, or active CNS lymphoma)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using immune cells from cord blood, called CAR NK cells, to fight certain types of B-cell lymphoma that have come back or not responded to other treatments. It is designed for people who have tried at least two prior therapies.
This trial tests a new treatment using specially engineered immune cells from cord blood to target and kill cancer cells in the brain or spine. It is for people whose central nervous system lymphoma has not responded to or has returned after previous treatments.
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
This trial tests a new combination treatment: first, natural killer cells (NK cells) that are engineered to find CD19, followed by CAR-T cells (also targeting CD19). It is for people with B-cell lymphoma that has come back or not responded to standard treatments.
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
This Phase 1 study tests a new immune-cell treatment made from donated cord blood. It aims to treat people whose B-cell lymphoma has come back or did not respond, specifically when the tumor has CD19 on it.
Hear when a new Refractory or Relapsed B-cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.